Published in Cancer Weekly, July 4th, 2006
Findings from the investigator-sponsored studies indicate that the combination regimens, known as TAXSAM, are well tolerated, provide pain palliation, and demonstrate promising rates of clinical and biochemical responses. Results were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.